Regeneron will be the final of 17 large pharmaceutical companies to sign such a drug pricing agreement with the Trump administration.

Regeneron is the latest in a string of major drugmakers to make pricing concessions for new and existing medicines under agreements with Trump.

On Thursday, President Donald Trump announced a new drug price deal with Regeneron, the latest company to agree to a new price policy push.